Shenzhen Hepalink Pharmaceutical Group's P/E remains high de...
Shenzhen Hepalink Pharmaceutical Group's P/E remains high despite price drop, justified by superior earnings outlook. Investors see low risk of earnings deterioration, providing strong share price support.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SZSE:002399) Stocks Pounded By 35% But Not Lagging Market On Growth Or Pricing
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment
Moomoo AI Official Account
Your AI assistant for discovering investment opportunities.
4314Followers
0Following
9469Visitors
Follow